13 May, 2017
Comparatively, Bristol-Myers Squibb Company posted earnings of $0.84 per share in the same quarter previous year. First Command Financial Services Inc.'s holdings in Bristol-Myers Squibb were worth $174,000 at the end of the most recent reporting period.
COPYRIGHT VIOLATION WARNING: "Norway Savings Bank Continues to Hold Stake in Bristol-Myers Squibb Co (BMY)" was first published by The Cerbat Gem and is owned by of The Cerbat Gem. Stockman Asset Management now owns 35,425 shares of the biopharmaceutical company's stock worth $1,910,000 after buying an additional 20,950 shares during the period.
Relative strength index (RSI-14) for Bristol-Myers Squibb Company (BMY) is at 53.62. Looking at this figure it suggests that the shares of Bristol-Myers Squibb Company (BMY) may be overvalued, however, this can also depend upon the situation of the market; if the market is strong then it could suggest that Bristol-Myers Squibb Company (BMY) is a good investment, however if the market is weaker then it could suggest that the shares are undervalued. However, the company's most recent quarter increase of 12.3% looks attractive. It traded with the volume of 2.04 Million shares in the last trading session as compared to average volume of 2190.19 shares. Shayne & CO. LLC now owns 4,017 shares of the biopharmaceutical company's stock valued at $218,000 after buying an additional 27 shares during the last quarter.
Bristol-Myers Squibb Co BMY (NYSE:BMY) has a 50 day moving average of 54.52 and a 200 day moving average of 54.99. (Nasdaq:CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, announced the companies have expanded their existing collaboration to evaluate Bristol-Myers Squibb's Opdivo in combination with Calithera's CB-839 in patients with non-small cell lung cancer (NSCLC) and melanoma. They expect $0.73 EPS, up 5.80% or $0.04 from last year's $0.69 per share. Finally, Gradient Investments LLC boosted its position in Bristol-Myers Squibb by 9.1% in the first quarter.
Investment analysts at Jefferies Group raised their FY2017 EPS estimates for Bristol-Myers Squibb in a research note issued on Monday. Welch Investments LLC acquired a new position in Bristol-Myers Squibb during the fourth quarter valued at $119,000. Neville Rodie & Shaw reported 0.7% in Bristol-Myers Squibb Co (NYSE:BMY). AlphaOne also assigned news coverage about the biopharmaceutical company an impact score of 82 out of 100, meaning that recent press coverage is very likely to have an effect on the stock's share price in the near future. It followed up with $1.13 billion in revenue during the first quarter of this year. This change led market cap to move at $91.94B, putting the price -26.77% below the 52-week high and 21.11% above the 52-week low. Jefferies Group LLC reaffirmed a "buy" rating and issued a $66.00 price objective (down previously from $69.00) on shares of Bristol-Myers Squibb in a report on Tuesday, January 31st. The biopharmaceutical company reported $0.84 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.72 by $0.12. BMY's profit will be $1.20 billion for 18.88 P/E if the $0.73 EPS becomes a reality. Fjarde Ap has 0.25% invested in TJX Companies Inc (NYSE:TJX) for 142,423 shares. The ex-dividend date of this dividend was Wednesday, April 5th. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is now sitting at 45. Over the short term, some market observers may have noticed that Bristol-Myers Squibb Company has a 1.36% short float with 15 days to cover. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of USA and worldwide copyright and trademark laws. Barclays Capital maintained the shares of BMY in report on Friday, September 9 with "Equal-Weight" rating. The original version of this article can be read at https://www.thecerbatgem.com/2017/05/13/norway-savings-bank-continues-to-hold-stake-in-bristol-myers-squibb-co-bmy.html. 12,000 shares valued at $681,240 were bought by Samuels Theodore R. II on Monday, February 27. Overall, 7.11 Million shares exchanged hands versus its average trading volume of 10.11 Million shares. $463,779 worth of Bristol-Myers Squibb Co (NYSE:BMY) was sold by Caldarella Joseph C. Following the completion of the sale, the director now owns 952,571 shares in the company, valued at $50,733,931.46. Following the transaction, the senior vice president now directly owns 55,637 shares of the company's stock, valued at approximately $3,187,443.73. The disclosure for this purchase can be found here.
Receive News & Ratings for Bristol-Myers Squibb Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co and related companies with MarketBeat.com's FREE daily email newsletter. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products.
